 | • レポートコード：TPM-B05028 • 出版社/出版日：Transparency Market Research / 2018年4月23日 • レポート形態：英文、PDF、155ページ • 納品方法：Eメール • 産業分類：Pharmaceutical |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、静脈内免疫グロブリン（IVIG）の世界市場について調べ、静脈内免疫グロブリン（IVIG）の世界規模、市場動向、市場環境、適応症別（慢性炎症性脱髄性多発性ニューロパチー（CIDP）、特発性血小板減少性紫斑病（ITP）、ギランバレー症候群、重症筋無力症、多巣性運動ニューロパチー（MMN）、川崎病、低ガンマグロブリン血症、慢性リンパ性白血病）分析、エンドユーザー別（病院、診療所、在宅ケア）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、バリューチェーン分析、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・静脈内免疫グロブリン（IVIG）の世界市場動向 ・静脈内免疫グロブリン（IVIG）の世界市場環境 ・静脈内免疫グロブリン（IVIG）のバリューチェーン分析 ・静脈内免疫グロブリン（IVIG）の世界市場規模 ・静脈内免疫グロブリン（IVIG）の世界市場規模：適応症別（慢性炎症性脱髄性多発性ニューロパチー（CIDP）、特発性血小板減少性紫斑病（ITP）、ギランバレー症候群、重症筋無力症、多巣性運動ニューロパチー（MMN）、川崎病、低ガンマグロブリン血症、慢性リンパ性白血病） ・静脈内免疫グロブリン（IVIG）の世界市場規模：エンドユーザー別（病院、診療所、在宅ケア） ・静脈内免疫グロブリン（IVIG）の世界市場：地域別市場規模・分析 ・静脈内免疫グロブリン（IVIG）の北米市場規模・予測 ・静脈内免疫グロブリン（IVIG）のアメリカ市場規模・予測 ・静脈内免疫グロブリン（IVIG）の中南米市場規模・予測 ・静脈内免疫グロブリン（IVIG）のヨーロッパ市場規模・予測 ・静脈内免疫グロブリン（IVIG）のアジア市場規模・予測 ・静脈内免疫グロブリン（IVIG）の日本市場規模・予測 ・静脈内免疫グロブリン（IVIG）の中国市場規模・予測 ・静脈内免疫グロブリン（IVIG）のインド市場規模・予測 ・静脈内免疫グロブリン（IVIG）の中東市場規模・予測 ・静脈内免疫グロブリン（IVIG）のアフリカ市場規模・予測 ・競争状況・関連企業情報 |
Intravenous Immunoglobulin (IVIG) Market: Scope and Methodology
This report on the global intravenous immunoglobulin (IVIG) market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global intravenous immunoglobulin (IVIG) market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the intravenous immunoglobulin (IVIG) market such as shift from intravenous to subcutaneous infusion of immunoglobulin. The key market indicators influencing global intravenous immunoglobulin (IVIG) market taken into consideration include prevalence of immunological disorders, global blood and plasma yield and geriatric population. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global intravenous immunoglobulin (IVIG) market. The report also highlights key events of the global intravenous immunoglobulin industry. A value chain analysis along with list of major players, hospitals and distributors is also included in the report.
Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2017 to 2024 are provided for all the segments, considering 2016 as the base year. The year on year growth of global intravenous immunoglobulin (IVIG) market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and growing number of acute and chronic patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.
Intravenous Immunoglobulin (IVIG) Market: Segmentation
Based on indication, the global intravenous immunoglobulin (IVIG) market has been segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. Based on end-user, the market has been segmented into hospitals, clinics, and home care. Hospitals segment is expected to remain dominant during the forecast period. However, home care segment is expected to grow at a higher CAGR than others.
Geographically, the global intravenous immunoglobulin (IVIG) market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.
Intravenous Immunoglobulin (IVIG) Market: Competitive Landscape
The report also profiles major players in the intravenous immunoglobulin (IVIG) market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the intravenous immunoglobulin (IVIG) market is provided in the report. The report also includes a competition matrix that provides insights into recent developments and activities done by the major market players. Key companies profiled in the report include Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V.
The global intravenous immunoglobulin (IVIG) market has been segmented as follows:
Global Intravenous immunoglobulin (IVIG) Market, by Indication
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Humoral Immunodeficiency
Idiopathic Thrombocytopenic Purpura (ITP)
Guillain-Barre Syndrome
Myasthenia Gravis
Multifocal Motor Neuropathy (MMN)
Kawasaki Disease
Hypogammaglobulinemia
Chronic Lymphocytic Leukemia
Others
Global Intravenous immunoglobulin (IVIG) Market, by End-user
Hospitals
Clinics
Home Care
Global Intravenous immunoglobulin (IVIG) Market, by Geography
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
Australia
India
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
South Africa
Saudi Arabia
Rest of Middle East & Africa
Section 1 Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights
Section 2 Assumptions and Research Methodology
2.1 Assumptions
2.2 Research Methodology
Section 3 Executive Summary
3.1 Global Intravenous Immunoglobulin (IVIG): Market Snapshot
3.2 Market Share Analysis by Region, 2015
3.3 Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Map
Section 4 Market Overview
4.1 Indication Overview
4.2 Global Intravenous Immunoglobulin (IVIG) Market: Key Industry Developments
4.3 Global Intravenous Immunoglobulin (IVIG) Market: Market Indicators
Section 5 Market Dynamics
5.1 Drivers and Restraints Snapshot Analysis
5.2 Drivers
5.2.1 Rise in prevalence of autoimmune disorders
5.2.2 Increase in global geriatric population
5.2.3 Growing usage in off-label indications
5.2.4 Improved technology for production and purification methods
5.2.5 Favorable government initiatives and approvals
5.2.6 Increase in health care spending & improving health care infrastructure
5.2.7 Rise in incidence of hematological, neurological disorders
5.3 Restraints
5.3.1 High cost of treatment
5.3.2 Chronic side effects
5.3.3 Supply demand gaps
5.3.4 Alternate therapies such as subcutaneous infusion IG (SCIG) and recombinant Indications
5.4 Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Analysis
5.5 Opportunities
5.5.1 Application in newer indications
5.5.2 Increasing global plasma yield to offer significant opportunities to new entrants
5.6 Key Trends
5.7 Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
5.8 Value Chain Analysis
5.9 Intravenous Immunoglobulin (IVIG) Market Outlook
Section 6 Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.1 Key Findings
6.2 Introduction
6.3 Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication
6.4 Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.4.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
6.4.2 Primary Humoral Immunodeficiency
6.4.3 Idiopathic Thrombocytopenic Purpura (ITP)
6.4.4 Guillain-Barre Syndrome
6.4.5 Myasthenia Gravis
6.4.6 Multifocal Motor Neuropathy (MMN)
6.4.7 Kawasaki Disease
6.4.8 Hypogammaglobulinemia
6.4.9 Chronic Lymphocytic Leukemia
6.4.10 Others
6.5 Market Attractiveness Analysis, by Indication
6.6 Key Trends
Section 7 Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.1 Key Findings
7.2 Introduction
7.3 Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user
7.4 Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.4.1 Hospitals
7.4.2 Clinics
7.4.3 Home Care
7.5 Market Attractiveness Analysis, by End-user
7.6 Key Trends
Section 8 Intravenous Immunoglobulin (IVIG) Market Analysis, by Region
8.1 Global Intravenous Immunoglobulin (IVIG) Market Snapshot, by Country
8.2 Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region
8.3 Intravenous Immunoglobulin (IVIG) Market Forecast, by Region
8.4 Market Attractiveness Analysis, by Region
Section 9 North America Intravenous Immunoglobulin (IVIG) Market Analysis
9.1 Key Findings
9.2 Market Overview
9.3 Market Analysis, by Indication
9.3.1 Market Value Share Analysis, by Indication
9.3.2 Market Size (US$ Mn) Forecast, by Indication
9.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.3.2.2 Primary Humoral Immunodeficiency
9.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
9.3.2.4 Guillain-Barre Syndrome
9.3.2.5 Myasthenia Gravis
9.3.2.6 Multifocal Motor Neuropathy (MMN)
9.3.2.7 Kawasaki Disease
9.3.2.8 Hypogammaglobulinemia
9.3.2.9 Chronic Lymphocytic Leukemia
9.3.2.10 Others
9.4 Market Analysis, by End-user
9.4.1 Market Value Share Analysis, by End-user
9.4.2 Market Size (US$ Mn) Forecast, by End-user
9.4.2.1 Hospitals
9.4.2.2 Clinics
9.4.2.3 Home Care
9.5 Market Analysis, by Country
9.5.1 Market Value Share Analysis, by Country
9.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
9.5.2.1 U.S.
9.5.2.2 Canada
9.6 Market Attractiveness Analysis
9.6.1 by Indication
9.6.2 by End-user
9.6.3 by Country
Section 10 Europe Intravenous Immunoglobulin (IVIG) Market Analysis
10.1 Key Findings
10.2 Market Overview
10.3 Market Analysis, by Indication
10.3.1 Market Value Share Analysis, by Indication
10.3.2 Market Size (US$ Mn) Forecast, by Indication
10.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.3.2.2 Primary Humoral Immunodeficiency
10.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
10.3.2.4 Guillain-Barre Syndrome
10.3.2.5 Myasthenia Gravis
10.3.2.6 Multifocal Motor Neuropathy (MMN)
10.3.2.7 Kawasaki Disease
10.3.2.8 Hypogammaglobulinemia
10.3.2.9 Chronic Lymphocytic Leukemia
10.3.2.10 Others
10.4 Market Analysis, by End-user
10.4.1 Market Value Share Analysis, by End-user
10.4.2 Market Size (US$ Mn) Forecast, by End-user
10.4.2.1 Hospitals
10.4.2.2 Clinics
10.4.2.3 Home Care
10.5 Market Analysis, by Country
10.5.1 Market Value Share Analysis, by Country
10.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
10.5.2.1 U.K.
10.5.2.2 Germany
10.5.2.3 France
10.5.2.4 Spain
10.5.2.5 Italy
10.5.2.6 Rest of Europe
10.6 Market Attractiveness Analysis
10.6.1 by Indication
10.6.2 by End-user
10.6.3 by Country
Section 11 Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
11.1 Key Findings
11.2 Market Overview
11.3 Market Analysis, by Indication
11.3.1 Market Value Share Analysis, by Indication
11.3.2 Market Size (US$ Mn) Forecast, by Indication
11.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.3.2.2 Primary Humoral Immunodeficiency
11.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
11.3.2.4 Guillain-Barre Syndrome
11.3.2.5 Myasthenia Gravis
11.3.2.6 Multifocal Motor Neuropathy (MMN)
11.3.2.7 Kawasaki Disease
11.3.2.8 Hypogammaglobulinemia
11.3.2.9 Chronic Lymphocytic Leukemia
11.3.2.10 Others
11.4 Market Analysis, by End-user
11.4.1 Market Value Share Analysis, by End-user
11.4.2 Market Size (US$ Mn) Forecast, by End-user
11.4.2.1 Hospitals
11.4.2.2 Clinics
11.4.2.3 Home Care
11.5 Market Analysis, by Country
11.5.1 Market Value Share Analysis, by Country
11.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
11.5.2.1 China
11.5.2.2 Japan
11.5.2.3 Australia
11.5.2.4 India
11.5.2.5 Rest of Asia Pacific
11.6 Market Attractiveness Analysis
11.6.1 by Indication
11.6.2 by End-user
11.6.3 by Country
Section 12 Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
12.1 Key Findings
12.2 Market Overview
12.3 Market Analysis, by Indication
12.3.1 Market Value Share Analysis, by Indication
12.3.2 Market Size (US$ Mn) Forecast, by Indication
12.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.3.2.2 Primary Humoral Immunodeficiency
12.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
12.3.2.4 Guillain-Barre Syndrome
12.3.2.5 Myasthenia Gravis
12.3.2.6 Multifocal Motor Neuropathy (MMN)
12.3.2.7 Kawasaki Disease
12.3.2.8 Hypogammaglobulinemia
12.3.2.9 Chronic Lymphocytic Leukemia
12.3.2.10 Others
12.4 Market Analysis, by End-user
12.4.1 Market Value Share Analysis, by End-user
12.4.2 Market Size (US$ Mn) Forecast, by End-user
12.4.2.1 Hospitals
12.4.2.2 Clinics
12.4.2.3 Home Care
12.5 Market Analysis, by Country
12.5.1 Market Value Share Analysis, by Country
12.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
12.5.2.1 Brazil
12.5.2.2 Mexico
12.5.2.3 Rest of LATAM
12.6 Market Attractiveness Analysis
12.6.1 by Indication
12.6.2 by End-user
12.6.3 by Country
Section 13 Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.1 Key Findings
13.2 Market Overview
13.3 Market Analysis, by Indication
13.3.1 Market Value Share Analysis, by Indication
13.3.2 Market Size (US$ Mn) Forecast, by Indication
13.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.3.2.2 Primary Humoral Immunodeficiency
13.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
13.3.2.4 Guillain-Barre Syndrome
13.3.2.5 Myasthenia Gravis
13.3.2.6 Multifocal Motor Neuropathy (MMN)
13.3.2.7 Kawasaki Disease
13.3.2.8 Hypogammaglobulinemia
13.3.2.9 Chronic Lymphocytic Leukemia
13.3.2.10 Others
13.4 Market Analysis, by End-user
13.4.1 Market Value Share Analysis, by End-user
13.4.2 Market Size (US$ Mn) Forecast, by End-user
13.4.2.1 Hospitals
13.4.2.2 Clinics
13.4.2.3 Home Care
13.5 Market Analysis, by Country
13.5.1 Market Value Share Analysis, by Country
13.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
13.5.2.1 South Africa
13.5.2.2 Saudi Arabia
13.5.2.3 Rest of MEA
13.6 Market Attractiveness Analysis
13.6.1 by Indication
13.6.2 by End-user
13.6.3 by Country
Section 14 Company Profiles
14.1 Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2015)
14.2 Competition Matrix
14.3 Company Profiles
14.3.1 Baxalta Incorporated
14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2 Financial Overview
14.3.1.3 Product Portfolio
14.3.1.4 SWOT Analysis
14.3.1.5 Strategic Overview
14.3.2 Biotest AG
14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2 Financial Overview
14.3.2.3 Product Portfolio
14.3.2.4 SWOT Analysis
14.3.2.5 Strategic Overview
14.3.3 China Biologic Products, Inc.
14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2 Financial Overview
14.3.3.3 Product Portfolio
14.3.3.4 SWOT Analysis
14.3.3.5 Strategic Overview
14.3.4 CSL Behring LLC
14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2 Financial Overview
14.3.4.3 Product Portfolio
14.3.4.4 SWOT Analysis
14.3.4.5 Strategic Overview
14.3.5 Grifols S.A.
14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2 Financial Overview
14.3.5.3 Product Portfolio
14.3.5.4 SWOT Analysis
14.3.5.5 Strategic Overview
14.3.6 Kedrion S.p.A.
14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2 Financial Overview
14.3.6.3 Product Portfolio
14.3.6.4 SWOT Analysis
14.3.6.5 Strategic Overview
14.3.7 LFB Biomedicaments S.A.
14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2 Financial Overview
14.3.7.3 Product Portfolio
14.3.7.4 SWOT Analysis
14.3.7.5 Strategic Overview
14.3.8 Octapharma AG
14.3.8.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2 Financial Overview
14.3.8.3 Product Portfolio
14.3.8.4 SWOT Analysis
14.3.8.5 Strategic Overview
14.3.9 Sanquin Plasma Products B.V.
14.3.9.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2 Financial Overview
14.3.9.3 Product Portfolio
14.3.9.4 SWOT Analysis
14.3.9.5 Strategic Overview
Table 01: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 02: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 03: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 04: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 05: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 06: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 07: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 08: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 09: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 10: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 11: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 12: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 13: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2014–2024
Table 14: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 15: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 16: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication Type, 2014–2024
Table 17: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 18: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2014–2024